ArticlePlants (Basel, Switzerland)2022
An In-Depth Study of Metabolite Profile and Biological Potential of
Article in Plants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Article
- Advancing the Potential ofPlants (Basel, Switzerland) · 2026Article
- Bioactive Aromatic Plant Extracts Modulate Metabolism and Inflammation in HeLa Cells.Molecules (Basel, Switzerland) · 2025Article
- Insight into Cytotoxic Potential ofPlants (Basel, Switzerland) · 2025Article
- Article
- Nephroprotective Effects ofCurrent issues in molecular biology · 2025Article
- Impact of Sustainable Soil Cropping Management on the Production and Stability of Bioactive Compounds inPlants (Basel, Switzerland) · 2025Article
- Evaluation of the Influence ofMolecules (Basel, Switzerland) · 2024Article
- Mitigating Effects ofPlants (Basel, Switzerland) · 2024Article
- Article
- Phytochemical Investigation of Polyphenols from the Aerial Parts ofPlants (Basel, Switzerland) · 2024Article
- Secondary metabolic profiling, antioxidant potential, enzyme inhibitory activities and in silico and ADME studies: a multifunctional approach to reveal medicinal and industrial potential of Tanacetum falconeri.BMC complementary medicine and therapies · 2024Article
- A Comprehensive Phytochemical Analysis ofMolecules (Basel, Switzerland) · 2023Article
- A Comparative Study on UHPLC-HRMS Profiles and Biological Activities ofAntioxidants (Basel, Switzerland) · 2023Article
- UHPLC-ESI-QTOF-MS/MS Profiling of Phytochemicals from Araticum Fruit (Foods (Basel, Switzerland) · 2023Article
- The Phytochemical Profiling, In Vitro Antioxidant, and Hepatoprotective Activity ofInternational journal of molecular sciences · 2023Article
- Phytochemical Profiling, Antioxidant and Cognitive-Enhancing Effect ofPlants (Basel, Switzerland) · 2023Article
- Antioxidant and Hepatoprotective Potential ofInternational journal of molecular sciences · 2023Article
- Metabolite profiling and bioactivity ofPlants (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Asteraceae species Tanacetum balsamita L. (costmary) is renowned for its traditional usage as an aromatic, carminative and tonic plant. This work aimed at in-depth study of the phytochemical and in vitro biological profilings of methanol−aqueous extracts from the costmary leaves, flower heads and roots. An UHPLC-HRMS analysis revealed more than 100 secondary metabolites including 24 acylquinic acids, 43 flavonoid glycosides, aglycones and methoxylated derivatives together with 15 phenolic acids glycosides. For the first time, 91 compounds are reported in the costmary. The flower heads extract possessing the highest content of total phenolics and flavonoids, actively scavenged DPPH (84.54 ± 3.35 mgTE/g) and ABTS radicals (96.35 ± 2.22 mgTE/g), and showed the highest reducing potential (151.20 and 93.22 mg TE/g for CUPRAC and FRAP, respectively). The leaves extract exhibited the highest inhibition towards acetyl- and butyrylcholinesterase (2.11 and 2.43 mg GALAE/g, respectively) and tyrosinase (54.65 mg KAE/g). The root extract inhibited α-glucosidase (0.71 ± 0.07 mmol ACAE/g), α-amylase (0.43 ± 0.02 mmol ACAE/g) and lipase (8.15 ± 1.00 mg OE/g). At a concentration >2 µg/mL, a significant dose dependent reduction of cell viability towards THP-1 monocyte leukemic cells was observed. Costmary could be recommended for raw material production with antioxidant and enzyme inhibitory properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.